University of Kentucky Center for Cancer Metabolism

肯塔基大学癌症代谢中心

• 批准号: 10271864
• 负责人: DARET K ST CLAIR
• 金额: $ 228.97万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10271864
• 关键词: Address; Applications Grants; Area; Basic Science; Biochemistry; Bioinformatics; Biology; Biometry; Cancer Center; Cell Survival; Centers of Research Excellence; Clinical; Clinical Trials; Collaborations; Core Facility; Coupled; Data; Development; Disease; Distant Metastasis; Drug resistance; Early Diagnosis; Educational workshop; Environment; Epigenetic Process; Equipment; Extramural Activities; Faculty; Fees; Fostering; Foundations; Funding; Goals; Grant; Growth; Health; Image; Incidence; Infrastructure; Interdisciplinary Study; Intervention; Kentucky; Lead; Link; Malignant Neoplasms; Mediator of activation protein; Mentors; Metabolic; Metabolic Diseases; Metabolism; Methodology; NCI Center for Cancer Research; Neoplasm Metastasis; Obesity; Outcome; Oxidation-Reduction; Phase; Pilot Projects; Positioning Attribute; Protein Array; Quality of life; Recurrence; Research; Research Personnel; Research Project Grants; Research Support; Role; Scientist; Seeds; Services; Signal Transduction; System; Therapeutic; Training; Translational Research; Translations; United States National Institutes of Health; Universities; Vital capacity; animal imaging; anticancer research; base; cancer cell; cancer imaging; cancer initiation; cancer prevention; cancer therapy; career; cohesion; defined contribution; early detection biomarkers; editorial; improved; in vivo; innovation; metabolic imaging; metabolomics; mortality; multidisciplinary; new technology; next generation; novel; prevent; programs; recruit; skills; success; symposium; synergism; therapeutic target; therapy resistant; tool; tumor; tumor initiation; tumor metabolism; tumorigenesis

PROJECT SUMMARY The University of Kentucky (UK) Center of Biomedical Research Excellence on Cancer and Metabolism (CCM) was established in March 2017 by a multidisciplinary team of basic and clinical scientists engaged in cutting- edge research on metabolic dysregulations in cancer, an emerging hallmark of disease responsible for tumor development, drug resistance and distant metastasis. The overarching goal of the Phase II CCM is to continue efforts to expand a thematically focused multidisciplinary infrastructure dedicated to defining the contribution of metabolism in the development and treatment of cancer and to use this novel multidisciplinary platform to develop promising project leaders with enhanced skills in an exciting new area of cancer research. With a dedicated team of mentors combining basic and clinical expertise in redox biology, cancer cell signaling, epigenetics, systems biochemistry and clinical trials, as well as core strengths in advanced metabolomics and sophisticated cancer imaging, we will accomplish this overall goal by conducting high-quality basic and translational research addressing metabolic reprogramming governing tumor initiation, metastasis, drug resistance and recurrence. This objective will be met by achieving 2 Specific Aims. Specific Aim 1 is to expand the critical mass of investigators conducting CCM thematic research. We will recruit, coach and solidify the commitment of a cadre of promising project leaders to conduct cancer and metabolism research utilizing a highly effective mentoring system and provide these scientists with cutting-edge research core facilities and services. Proposed new synergies will be developed through 4 well-crafted research projects; an Administrative Core; innovative research cores in metabolism and imaging; strong biostatistics and bioinformatics support; and collaborations with other UK research centers to facilitate the translation of basic findings in cancer metabolism into early therapeutic and/or intervention approaches. Specific Aim 2 is to advance an independent, sustainable, multidisciplinary thematic biomedical infrastructure and research program on cancer and metabolism by strengthening key scientific cores. We propose to expand the scope and capacity of these vital cores by acquiring and installing new state-of-the-art equipment, introducing new technologies and service as well as providing training sessions, workshops and symposiums. Kentucky ranks highest in rates of overall cancer incidence and mortality [1]. In Phase I, the CCM had a transformative impact in career research and retention of the next generation of scientists who address metabolic dysregulations underpinning the causal links between metabolic disorders and cancer development, a major health threat in the nation. Importantly, the Phase II application will build upon these accomplishments to propel CCM to a nationally recognized center in cancer and metabolism research that will also address the region’s critical needs.

项目摘要 肯塔基大学（英国）生物医学研究中心癌症与代谢卓越（CCM） 由一支由基础和临床科学家组成的多学科团队于2017年3月成立 癌症代谢失调的边缘研究，癌症的新兴标志是肿瘤 发育，耐药性和远处转移。第二阶段CCM的总体目标是继续 扩大主题集中的多学科基础设施的努力，该基础设施致力于定义的贡献 在癌症发展和治疗中的代谢，并使用这个新颖的多学科平台 在令人兴奋的新的癌症研究领域中，发展有望的项目领导者具有提高技能。与 专门的导师团队结合了氧化还原生物学，癌细胞信号传导的基本和临床专业知识， 表观遗传学，系统生物化学和临床试验，以及高级代谢组学的核心优势 软化癌症成像，我们将通过进行高质量的基本和 转化研究涉及代谢重编程管理肿瘤倡议，转移，药物 阻力和复发。实现2个特定目标将实现这一目标。特定目标1是扩展 进行CCM主题研究的研究人员的关键质量。我们将招募，教练和巩固 承诺的项目负责人的承诺对进行癌症和代谢研究的承诺使用高度 有效的心理系统，并为这些科学家提供尖端的研究核心设施和服务。 拟议的新协同作用将通过4个精心制作的研究项目开发；行政核心； 新陈代谢和成像中的创新研究核心；强大的生物统计学和生物信息学支持；和 与其他英国研究中心的合作，以促进癌症代谢基本发现的翻译 进入早期的治疗和/或干预方法。特定目标2是促进独立，可持续的， 多学科主题生物医学基础设施和研究癌症和代谢研究计划 加强关键的科学核心。我们建议通过纳入这些重要核心的范围和能力 并安装新的最先进的设备，引入新技术和服务以及提供 培训课程，讲习班和研讨会。肯塔基州的总癌症事件发生率最高， 死亡率[1]。在第一阶段，CCM对职业研究和保留下一个有变革性的影响 应对代谢失调的科学家产生的代谢失调是代谢之间的因果关系 疾病和癌症发展，这是美国的主要健康威胁。重要的是，第二阶段的应用将 以这些成就为基础，将CCM推向癌症和新陈代谢的全国认可的中心 还将满足该地区关键需求的研究。